Abstracts tagged "microbiome and treatment"

Abstract Number: 2061 • 2016 ACR/ARHP Annual Meeting
Successful Treatment of Murine Lupus Nephritis with Helminths Related Tuftsin-Phosphorylcholine Compound and Its Effect on the Microbiota
Yehuda Shoenfeld¹, Tomer Bashi², Hadar Gershon³, Or Givol⁴, Alexander Volkov⁵, Iris Barshack⁵, Mati Fridkin⁶, Miri Blank² and Omry Koren⁷, ¹Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ²Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ³Sefat Medical School, Bar-Ilan University, Sefat, Israel, ⁴Zabludowicz Center for Autoimmune Diseases, Ramat Gan, Israel, ⁵Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ⁶Organic chemistry, Weizmann Institute for Sciences, Rehovot, Israel, ⁷Sefat medical school, Bar-Ilan university, Sefat, Israel
Background/Purpose: , In areas where helminths infections are common, autoimmune diseases are rare. Treatment with helminthes and their ova, improved clinical findings of inflammatory bowel…
Abstract Number: 957 • 2015 ACR/ARHP Annual Meeting
Double Blind Placebo Controlled Randomized Trial of Probiotics in Enthesitis-Related-Arthritis Category of JIA: Effect on Clinical and Immunological Parameters
Anuj Shukla¹, Priyanka Gaur² and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Gut microflora influences the development and homeostasis of the immune system. Dysbiosis has been reported in various immuno-inflammatory diseases. Pathogenesis of enthesitis-related-arthritis (ERA) category…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].